Patents by Inventor Ofra BENNY
Ofra BENNY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240077490Abstract: The technology subject of the present application generally concerns methods for in vivo or in vitro detection of cancer cells utilizing selective particle-uptake in cancer samples.Type: ApplicationFiled: October 11, 2020Publication date: March 7, 2024Inventors: Ofra BENNY, Yifat BRILL KARNIELY
-
Publication number: 20220296543Abstract: Provided are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.Type: ApplicationFiled: August 12, 2020Publication date: September 22, 2022Applicants: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Ofra BENNY, Sharon MERIMS, Yelena MOSTINSKI
-
Patent number: 10695462Abstract: The invention disclosed herein generally provides implantable medical devices and implants that may be removed on-demand from a subject's body at any time after their implanting in the body, without necessitating invasive procedures.Type: GrantFiled: October 7, 2015Date of Patent: June 30, 2020Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Oded Shoseyov, Danny Porath, Ofra Benny, Yaron Bar-Lavie, Amos Ofer
-
Publication number: 20170312388Abstract: The invention disclosed herein generally provides implantable medical devices and implants that may be removed on-demand from a subject's body at any time after their implanting in the body, without necessitating invasive procedures.Type: ApplicationFiled: October 7, 2015Publication date: November 2, 2017Applicants: Yissum Research Development company of the Hebrew University of Jerusalem Ltd., Rambam Med-Tech Ltd.Inventors: Oded SHOSEYOV, Danny PORATH, Ofra BENNY, Yaron BAR-LAVIE, Amos OFER
-
Patent number: 9789199Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: September 12, 2016Date of Patent: October 17, 2017Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Patent number: 9782489Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: August 26, 2016Date of Patent: October 10, 2017Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20160375144Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20160361428Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: August 26, 2016Publication date: December 15, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Patent number: 9446140Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: June 24, 2014Date of Patent: September 20, 2016Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20160136292Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: January 25, 2016Publication date: May 19, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra BENNY-RATSABY, Robert D'AMATO, Judah FOLKMAN
-
Patent number: 9272050Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: September 24, 2014Date of Patent: March 1, 2016Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20150104406Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: September 24, 2014Publication date: April 16, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Patent number: 8865151Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: December 28, 2009Date of Patent: October 21, 2014Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20140301969Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: June 24, 2014Publication date: October 9, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Patent number: 8790634Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: December 28, 2009Date of Patent: July 29, 2014Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20100158855Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: December 28, 2009Publication date: June 24, 2010Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20100111894Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: December 28, 2009Publication date: May 6, 2010Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato